HHS secretary states that federal regulations require the authorization of generics that are “identical to the brand-name drug.“
The Food and Drug Administration (FDA) approved a generic version of the abortion drug mifepristone this week, rolling out the decision with no official announcement.
In response to critics of the approval, Department of Health and Human Services Secretary Robert F. Kennedy, Jr., said the FDA’s decision to approve the drug was only “because federal law requires approval when an application proves the generic is identical to the brand-name drug.”
The FDA has launched a nationwide study into the risks of the abortion pill to women’s health, anticipating an update to its Risk Evaluation and Mitigation Strategy requirements. Insurance claim data indicate that nearly 11 percent of women who used mifepristone from 2017 to 2023 experienced serious health complications, including hemorrhage, sepsis, cardiac problems, or anaphylaxis. In almost 3 percent of cases, failure of the drug required surgical follow-up.
This original abortion pill was approved by the FDA in 2000.
As the Lord Leads, Pray with Us…
- For the Lord to guide HHS Secretary Kennedy and FDA Commissioner Makary as they conduct the risk assessment study on the abortion pill.
- For FDA officials to be discerning as they test and review approvals of prescriptions, medications, and therapies.
Sources: UPI News, The Hill,
